Full Press Release Details
DOYLESTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) --Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. The Company reported continued clinical progress across both its WEE1 and ATR inhibitor programs and has cash runway into the fourth quarter of 2026.
“We are pleased with the continued progress in our development programs, as the emerging data on both of our clinical assets demonstrate evidence of activity,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “For APR-1051, our WEE1 kinase inhibitor, we’re encouraged by early signs of anti-tumor activity to date in the ongoing ACESOT-1051 trial, including 3 out of 4 patients with stable disease in the 100 mg once daily cohort. We have recently advanced into the 150 mg once daily cohort as dose escalation in this trial continues. For ATR-119, identifying the recommended Phase 2 dose for the once daily (QD) dosing provides a solid foundation for next-stage development, and we are now considering potential combination strategies, with radiation or checkpoint inhibitors, that could expand its clinical impact. These developments reinforce Aprea’s differentiated DDR approach and our commitment to helping patients with value creating clinical catalysts anticipated in 2026.”
Key Business Updates and Potential Upcoming Key Milestones
ACESOT-1051: A Biomarker Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051
ABOYA-119: Ongoing Clinical Trial Evaluating ATR inhibitor, ATRN-119
Select Financial Results for the Third quarter Ended September 30, 2025
About ApreaAprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website atwww.aprea.com.
The Company may use, and intends to use, its investor relations website athttps://ir.aprea.com/as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking StatementCertain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
| Aprea Therapeutics, Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | (unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,718,052 | $ | 22,849,885 | ||||
| Prepaid expenses and other current assets | 225,936 | 726,254 | ||||||
| Total current assets | 13,943,988 | 23,576,139 | ||||||
| Property and equipment, net | 65,236 | 81,522 | ||||||
| Restricted cash | 40,930 | 40,170 | ||||||
| Other noncurrent assets | 271,162 | 281,662 | ||||||
| Total assets | $ | 14,321,316 | $ | 23,979,493 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 641,322 | $ | 1,352,240 | ||||
| Accrued expenses | 2,039,785 | 2,008,735 | ||||||
| Total current liabilities | 2,681,107 | 3,360,975 | ||||||
| Commitments and contingencies | ||||||||
| Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 and 56,227 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 727,361 | 1,311,063 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock, $0.001 par value, 400,000,000 shares authorized, 5,979,292 and 5,481,055 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 5,979 | 5,481 | ||||||
| Additional paid-in capital | 352,722,214 | 350,971,225 | ||||||
| Accumulated other comprehensive loss | (10,629,534 | ) | (10,627,379 | ) | ||||
| Accumulated deficit | (331,185,811 | ) | (321,041,872 | ) | ||||
| Total stockholders’ equity | 10,912,848 | 19,307,455 | ||||||
| Total liabilities and stockholders' equity | $ | 14,321,316 | $ | 23,979,493 |
| Aprea Therapeutics, Inc. | ||||||||||||||||
| Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Grant revenue | $ | 1,848 | $ | 354,621 | $ | 282,422 | $ | 1,296,764 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,638,917 | 2,846,399 | 6,034,196 | 7,004,451 | ||||||||||||
| General and administrative | 1,480,319 | 1,605,238 | 4,838,969 | 5,385,923 | ||||||||||||
| Total operating expenses | 3,119,236 | 4,451,637 | 10,873,165 | 12,390,374 | ||||||||||||
| Loss from operations | (3,117,388 | ) | (4,097,016 | ) | (10,590,743 | ) | (11,093,610 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income, net | 150,669 | 348,741 | 533,422 | 1,014,518 | ||||||||||||
| Foreign currency (loss) gain | (5,691 | ) | (35,494 | ) | (86,618 | ) | 15,180 | |||||||||
| Total other income | 144,978 | 313,247 | 446,804 | 1,029,698 | ||||||||||||
| Net loss | $ | (2,972,410 | ) | $ | (3,783,769 | ) | $ | (10,143,939 | ) | $ | (10,063,912 | ) | ||||
| Other comprehensive loss: | ||||||||||||||||
| Foreign currency translation | (1,117 | ) | 23,557 | (2,155 | ) | 6,526 | ||||||||||
| Total comprehensive loss | $ | (2,973,527 | ) | $ | (3,760,212 | ) | $ | (10,146,094 | ) | $ | (10,057,386 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.47 | ) | $ | (0.64 | ) | $ | (1.65 | ) | $ | (1.88 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 6,372,938 | 5,939,755 | 6,151,433 | 5,360,579 |